Promiliad Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.5M

  • Investors
  • 4

Promiliad General Information

Description

Developer of a drug discovery platform designed to focus on the development of new antibacterial and antifungal agents. The company's platform uses a technology called ReBACS which offers a complex and rich structural diversity, enabling scientists to simplify the synthetic challenge in drug discovery and increasing the probability of generating new lead compounds.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 950 West Fork Petty Creek Road
  • Alberton, MT 59820
  • United States
+1 (406) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Promiliad Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Grant 01-Sep-2020 $1.5M Completed Generating Revenue
10. Grant 04-Apr-2019 00.000 Completed Generating Revenue
9. Grant 01-Sep-2018 00000 Completed Generating Revenue
8. Later Stage VC Completed Generating Revenue
7. Grant 15-Jul-2016 00000 Completed Generating Revenue
6. Grant 01-Jul-2013 00000 Completed Generating Revenue
5. Grant 01-Jul-2011 00.000 Completed Generating Revenue
4. Grant 15-Jul-2009 00000 Completed Generating Revenue
3. Grant 01-Jan-2006 $2.56M Completed Startup
2. Grant 15-Jul-2005 $474K Completed Startup
To view Promiliad’s complete valuation and funding history, request access »

Promiliad Patents

Promiliad Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-9382213-B2 Heterocyclic and cyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase Active 12-Feb-2014 0000000000 0
US-20150225353-A1 Heterocyclic and cyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase Active 12-Feb-2014 0000000000 0

Promiliad Executive Team (3)

Name Title Board Seat Contact Info
Priestley Nigel Founder, Owner & Chief Executive Officer
Stephen Bergmeier Ph.D Chief Operating Officer & Director of Medicinal Chemistry
Mark McMills Ph.D Chief Security Officer
To view Promiliad’s complete executive team members history, request access »

Promiliad Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Promiliad Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institute Of Allergy and Infectious Diseases Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
TechGROWTH Ohio Not-For-Profit Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Promiliad’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »